Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feature Articles

More »
Feb 15, 2010 (Vol. 30, No. 4)

Refined Tools Aid in Pathway Analysis

Scientists Explore Range of Options to Remove Roadblocks Along the New Product Development Highway

  • Effects of HSP90 Inhibition

    Click Image To Enlarge +
    A merged multichannel image of lung cancer cells stained for DNA and for cell-cycle phase markers (Exelixis)

    Susan Lyman, Ph.D., research scientist at Exelixis, presented a cell-cycle analysis method that she and her colleagues developed. “This new method allows us to easily profile cell-cycle perturbations in a large number of samples, with improved throughput and greater information content versus classical methods of cell-cycle analysis like FACS.”

    Dr. Lyman noted that cell-cycle analysis has traditionally been carried out by fluorescence activated cell sorting (FACS). The new method, in contrast, uses image-based assessment of fluorescently labeled cells, combining a measurement of DNA content with imaging of several phase-specific readouts.

    “The end result is a novel and robust high-throughput Cellomics-based cell-cycle assay that reports the phase status of a cell as well as its DNA content.” Dr. Lyman and her colleagues applied this technique to examine the cell-cycle perturbations caused by inhibition of HSP90, a molecular chaperone that enhances the stability of client proteins. 

    “We used the high-content cell-cycle method to analyze the cell-cycle effects of several different small molecule inhibitors of HSP90 in a large panel of cancer cell lines and were amazed at how distinct HSP90 inhibitors yielded nearly identical cell-cycle phenotypes. It’s been a very useful tool for profiling small molecules,” Dr. Lyman insisted.

    “In developing this cell-cycle analysis method, we tried to combine the best aspects of FACS and the best aspects of high-content imaging to generate high-quality cell-profiling data for our internal preclinical studies. Essentially, we have created a new application of some existing technologies to produce an efficient and robust means of assessing cell-cycle perturbations to help drive our preclinical development.”

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »